400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
Announces Second Quarter 2025 Results and Provides Business Update
Changes in Board, Management or Compensation
Other Events
Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
Announces First Quarter 2025 Results and Provides Business Update
Amended material disclosure
Announces Closing of Merger
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities
S-1
Prospectus Filed Pursuant to Rule 425
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
S-4/A
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership